Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 13

Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus

Authors Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA

Received 14 March 2020

Accepted for publication 1 May 2020

Published 28 May 2020 Volume 2020:13 Pages 1855—1861

DOI https://doi.org/10.2147/DMSO.S253967

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Ming-Hui Zou


Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Kaleab Alemayehu Zewdie, Brhane Teklebrhan Assefa, Muluken Altaye Ayza

Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia

Correspondence: Gebrehiwot Gebremedhin Tafere
Department of Pharmacology and Toxicology,School of Pharmacy, Mekelle University, P.O. Box: 1871, Mekelle, Ethiopia
Tel +251 908822323
Email gebrehiwotg07@gmail.com

Abstract: Diabetes mellitus (DM) is a worldwide health threat affecting millions of people, which is associated with different micro- and macro-vascular complications. Type 2 diabetes mellitus (T2DM) is one of the different types of DM caused by insulin resistance and/or reduced secretion of insulin from the pancreas. A validated novel biomarker is required to enhance the accuracy of disease prediction, provide novel insights into pathophysiology and contribute to future prevention of T2DM. Various newer diagnostic methods have been developed by targeting endogenous proteins among which Adipsin is one of the promising target. Therefore, this review discusses Adipsin as a potential biomarker and its implication in T2DM. Adipsin is one of the adipokines secreted by adipose tissues which is involved in maintaining adipose tissue homeostasis and increasing insulin secretion in response to glucose. According to different experimental and clinical studies, plasma Adipsin concentrations are low in animals and patients with DM which support its use as a biomarker in combination to the other diagnostic modalities for DM. Additionally, the existence of Adipsin could be important in improving hyperglycemia by preserving β-cell mass through improving β-cell survival and maintaining their transcriptional identity.

Keywords: adipsin, type 2 diabetes mellitus, biomarker

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]